Hydroxycut Recall Eyed As Trigger For Closer Look At Supplement AERs
This article was originally published in The Tan Sheet
Executive Summary
The dietary supplement industry looks to FDA's Hydroxycut investigation for a sign on whether the agency will analyze adverse event reports more closely following a high-profile product recall
You may also be interested in...
U.S. Military Investigates Supplement Ingredient DMAA, Bans Sales
DoD suspends DMAA sales at military stores after regulators in Canada and New Zealand restricted access and as some U.S. firms change how they market and label the ingredient. These moves and the potential for an FDA review could lead to enforcement against DMAA similar to the 2004 ban against ephedra’s use in supplements.
U.S. Military Investigates Supplement Ingredient DMAA, Bans Sales
DoD suspends DMAA sales at military stores after regulators in Canada and New Zealand restricted access and as some U.S. firms change how they market and label the ingredient. These moves and the potential for an FDA review could lead to enforcement against DMAA similar to the 2004 ban against ephedra’s use in supplements.
Durbin Requests GAO Inquiry On Supplement Adverse Event Reports
Sen. Durbin says it is unclear how FDA’s adverse event reporting system works to protect consumer safety and asks GAO to investigate the agency’s collection and analysis of dietary supplement AERs.